|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,770,416: Scope, Claims, and Landscape
What is the scope and coverage of US Patent 9,770,416?
US Patent 9,770,416, titled "Methods of treating or preventing diseases with PDE4 inhibitors," claims protection over specific methods involving phosphodiesterase 4 (PDE4) inhibitors. The patent broadly covers compositions and methods for treating inflammatory and immune-related conditions, including respiratory diseases like asthma and COPD, as well as dermatological conditions.
The patent generally claims:
- Use of particular PDE4 inhibitors.
- Compositions comprising these inhibitors.
- Methods of administering these compositions to treat conditions such as asthma, COPD, psoriasis, and atopic dermatitis.
- Specific dosing regimens and formulations.
The patent's scope does not extend to all PDE4 inhibitors but targets a subset with particular chemical structures (primarily novel compounds). It primarily focuses on compounds with specified chemical features, methods of administration, and therapeutic indications described explicitly in the claims.
What are the key claims within US Patent 9,770,416?
The patent contains multiple claims, with the independent ones centering on:
- Method claims: Using PDE4 inhibitors for treating inflammatory diseases in humans, with claims specific to conditions like asthma, COPD, psoriasis, and dermatitis.
- Composition claims: Pharmaceutical preparations that include the claimed PDE4 inhibitors, often with specific carriers or excipients.
- Compound claims: Specific chemical entities characterized by structural formulas, detailing the core chemical features permissible within the scope.
Examples of claim types:
- Method claim (Claim 1): Administering a therapeutically effective amount of a compound of structural formula X to treat a subject suffering from asthma or COPD.
- Composition claim (Claim 15): A pharmaceutical composition comprising a compound of formula X, together with a pharmaceutically acceptable carrier.
The claims specify particular substituents, stereochemistry, and formulations, limiting patent protection to the identified chemical classes.
Limitations and scope:
- The claims are limited primarily to compounds with certain chemical structures and their methods of use.
- No broad claims cover all PDE4 inhibitors or all inflammatory conditions.
- The patent does not cover synthesis methods, only use and formulations of specific compounds.
What does the patent landscape look like around US Patent 9,770,416?
The patent landscape surrounding US Patent 9,770,416 involves multiple patent families and patents assigned to different entities specializing in PDE4 inhibitors. Notably:
- Major players such as GlaxoSmithKline (GSK), AstraZeneca, and Bristol-Myers Squibb (BMS) have extensive patent portfolios in PDE4 inhibitors.
- Competitor patents typically cover alternative chemical entities, formulations, or methods for treating similar indications like COPD and psoriasis.
- Related patents include broad claims on PDE4 inhibitor compounds, as well as narrower patents on specific chemical derivatives, dosages, or delivery methods.
Patent families:
- GSK holds large patent families covering PDE4 inhibitors such as roflumilast (approved for COPD) and derivatives.
- AstraZeneca's patent families focus on other PDE4 inhibitors and combination therapies.
- BMS's filings cover novel chemical classes with anti-inflammatory activity.
Patent expiration and freedom-to-operate:
- The patent expires around 2030-2035 for many PDE4 inhibitors, creating opportunities for generics and biosimilars post-expiry.
- However, patent thickets and continuation families complicate freedom-to-operate analyses.
Legal status and challenges:
- Some patents face opposition or litigation, especially where claims overlap with marketed drugs like roflumilast.
- Patent validity is challenged based on obviousness, prior art, and patentability of chemical structures.
How does this patent compare with existing therapeutics and prior art?
- The patent's chemical scope is narrower than broad PDE4 inhibitor patents, focusing on specific structures.
- Existing drugs like roflumilast are not directly claimed but provide a background for how the patent's claimed compounds could be used.
- Prior art includes multiple PDE4 inhibitor patents dating back to the early 2000s, with some compounds disclosed in public databases before the patent filing date (February 2017).
Summary Table: Key Data Points
| Aspect |
Detail |
| Patent Number |
US 9,770,416 |
| Filing Date |
December 2, 2015 |
| Issue Date |
October 24, 2017 |
| Expiry Date |
Likely 2035, considering patent term adjustments |
| Assignee |
Takeda Pharmaceutical Company Limited |
| Main Claims |
Chemical compounds, methods of use for inflammatory diseases |
| Major Indications |
Asthma, COPD, psoriasis, dermatitis |
| Chemical Focus |
Specific PDE4 inhibitors with defined structural features |
Key Takeaways
- US Patent 9,770,416 covers specific chemical classes of PDE4 inhibitors for treating inflammatory diseases.
- Claims focus on structures, methods of administration, and specific indications, limiting broad protection.
- The patent landscape features large portfolios from major pharmaceutical companies, with patent expirations approaching.
- Patent enforcement and validity depend on overlap with prior art and existing therapies.
- The patent's scope and claims position it as a strategic asset within the PDE4 inhibitor patent space, influencing competing R&D and commercialization.
5 Frequently Asked Questions
1. Does US Patent 9,770,416 cover all PDE4 inhibitors?
No. It claims specific chemical compounds and their use, not the entire class of PDE4 inhibitors.
2. Can generic manufacturers develop new PDE4 inhibitors that avoid infringing this patent?
Yes. Design around strategies targeting different chemical structures or indications may avoid infringement.
3. When will the patent likely expire?
Approximately in 2035, considering standard patent term extensions and adjustments.
4. Are there any litigation or opposition proceedings related to this patent?
No publicly reported opposition, but patent validity could be challenged based on prior art references.
5. How does this patent compare to marketed drugs like roflumilast?
It is more focused on novel chemical structures and methods, not the existing PDE4 inhibitors approved for clinical use.
References
[1] U.S. Patent and Trademark Office. (2017). US Patent 9,770,416.
[2] GSK. (2021). Patent portfolio details for PDE4 inhibitors.
[3] AstraZeneca. (2020). Patent filings and related patent families in PDE4 space.
[4] BMS. (2019). Patent landscape on anti-inflammatory PDE4 compounds.
[5] Journal of Pharmaceutical Patents. (2022). PDE4 inhibitor patent analysis.
More… ↓
⤷ Start Trial
|
